UPDATE: Goldman Sachs Downgrades Cardinal Health (CAH) to Neutral
- Tech, bank stocks drive Wall Street to new high
- Lower for longer, ECB scales back asset buys
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Oil rises above $50 despite doubts over OPEC output cut
- UPDATE: LPL Financial (LPLA) Said to Decide to Stay Independent After Reviewing Options - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Updated - September 16, 2016 8:33 AM EDT)
Goldman Sachs downgraded Cardinal Health (NYSE: CAH) from Conviction Buy to Neutral with a price target of $83 (prior $90). Analyst Robert P. Jones sees moderating brand pricing.
Jones explained, "We remove CAH from the Americas Conviction List and downgrade it to Neutral (from Buy) as softer brand price inflation presents an additional risk to earnings in a year when EPS growth was already below CAH’s long-term (3-year) target of 10-15%. Further, a more permanent change in brand pricing could present a structural headwind to the current earnings growth model. In addition, the upside drivers of EPS that we identified in our December 2015 upgrade have not been as accretive as expected (Cordis, Medical), with CAH recently lowering guidance for Cordis accretion in FY17."
Shares of Cardinal Health closed at $76.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades Timken (TKR) to Hold
- BMO Capital Remains Sidelined on United Natural Foods (UNFI) Following 1Q EPS Miss
- Mizuho Securities Upgrades Tailored Brands (TLRD) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Analyst PT Change, Downgrades
Related EntitiesGoldman Sachs Conviction Buy List, Goldman Sachs, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!